Search
Mirum Pharmaceuticals Inc
MIRMAdd to Watchlist
123.770USD
0.0000.00%
Close 06/26, 16:00（ET）Quotes delayed by 15 min
7.54BMarket Cap
LossP/E TTM
More Details of Mirum Pharmaceuticals Inc Company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the treatment of rare diseases affecting children and adults. It has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The Company is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Mirum Pharmaceuticals Inc Info
Ticker SymbolMIRM
Company nameMirum Pharmaceuticals Inc
IPO dateJul 18, 2019
CEOPeetz (Christopher)
Number of employees322
Security typeOrdinary Share
Fiscal year-endJul 18
Address989 East Hillsdale Boulevard, Suite 300
CityFOSTER CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94404
Phone16506674085
Websitehttps://mirumpharma.com/
Ticker SymbolMIRM
IPO dateJul 18, 2019
CEOPeetz (Christopher)
Company Executives of Mirum Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
52.37K
+32.44%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
47.13K
-5.53%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
Mr. Patrick J. Heron
Mr. Patrick J. Heron
Independent Director
Independent Director
5.70K
--
Dr. Laurent Fischer, M.D.
Dr. Laurent Fischer, M.D.
Independent Director
Independent Director
--
--
Dr. Pamela Vig, Ph.D.
Dr. Pamela Vig, Ph.D.
Chief Scientific Officer, Head of Research
Chief Scientific Officer, Head of Research
--
--
Ms. Lara Longpre
Ms. Lara Longpre
Chief Development Officer
Chief Development Officer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christopher (Chris) Peetz
Mr. Christopher (Chris) Peetz
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
389.76K
--
Mr. Michael G. (Mike) Grey
Mr. Michael G. (Mike) Grey
Independent Chairman of the Board
Independent Chairman of the Board
280.16K
--
Mr. Peter Radovich
Mr. Peter Radovich
President, Chief Operating Officer
President, Chief Operating Officer
52.37K
+32.44%
Mr. Eric H. Bjerkholt
Mr. Eric H. Bjerkholt
Chief Financial Officer
Chief Financial Officer
47.13K
-5.53%
Dr. Joanne Quan, M.D.
Dr. Joanne Quan, M.D.
Chief Medical Officer
Chief Medical Officer
28.65K
+55.50%
Ms. Laura A. Brege
Ms. Laura A. Brege
Independent Director
Independent Director
15.70K
--
FAQs
Who are the top five shareholders of Mirum Pharmaceuticals Inc?
The top five shareholders of Mirum Pharmaceuticals Inc are: Mr. Christopher (Chris) Peetz
How many institutions hold shares of Mirum Pharmaceuticals Inc (MIRM)?
As of 2026Q1, 541 institutions hold shares of Mirum Pharmaceuticals Inc, with a combined market value of approximately 68.01M, accounting for 111.53% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 4804206.00.
What is the biggest source of revenue for Mirum Pharmaceuticals Inc?
In 2026Q1, the Livmarli business generated the highest revenue for Mirum Pharmaceuticals Inc, amounting to 360.01M and accounting for 69.06% of total revenue.
